ReviewCancer letters2014
Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.
Review in Cancer letters, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 262 citations in OpenAlex.
- Oleanolic acid in the fight against cancer: a multifaceted natural strategy for modern oncology.Molecular diversity · 2026Review
- Design, Synthesis and Biological Evaluation of Novel Oleanolic Acid Derivatives as Potential Anti-Leukemic Agents.Life (Basel, Switzerland) · 2026Article
- Polymeric Nanocarriers and Polymer-Assisted Delivery Platforms for Oleanolic Acid: Design Strategies, Controlled Release, Translational Challenges, and Clinical Perspectives.Micromachines · 2026Review
- Oleanolic Acid Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by Inhibiting Ferroptosis through Targeting PTGS2 as a Key Molecular Node and Activating the AMPK/ACC Signaling Pathway.Journal of agricultural and food chemistry · 2026Article
- Bridging Two Worlds: Structural and Pharmacological Aspects of Natural Triterpenoid Dimers: Pristimerin-Pristimerin-Type Dimers.Molecules (Basel, Switzerland) · 2026Review
- Insights into the Recent Breakthroughs in Nanotechnological Outlook of Pentacyclic Triterpenoids: An Updated Approach.Current pharmaceutical design · 2026Review
- Participation of MDM2 in Pro-Apoptotic and Androgen Receptor- Degrading Potency of Selected Steroid and Terpenoid Derivatives.Current medicinal chemistry · 2026Review
- Pinto bean consumption mitigates colorectal tumorigenesis through reshaping gut microbiota and metabolic signatures.Current research in food science · 2026Article
- Design and synthesis of 3,4-seco-lupane triterpene-tryptamine derivatives and revealing their anti-bladder cancer mechanisms by combining TCGA and transcriptomic approaches.Scientific reports · 2025Article
- Cytotoxicity and Nanoassembly Characteristics of Aromatic Amides of Oleanolic Acid and Ursolic Acid.ACS omega · 2025Article
- Article
- Development of a Tandem Mass Spectral Library for the Detection of Triterpenoids in Plant Metabolome Based on Reference Standards.Plants (Basel, Switzerland) · 2024Article
- Principal Bioactive Properties of Oleanolic Acid, Its Derivatives, and Analogues.Molecules (Basel, Switzerland) · 2024Review
- Therapeutic potential of oleanolic acid in liver diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Oleanolic Acid Promotes the Formation of ProbioticMicroorganisms · 2024Article
- Unlocking the Potential of Oleanolic Acid: Integrating Pharmacological Insights and Advancements in Delivery Systems.Pharmaceutics · 2024Review
- Adherence to the Mediterranean Diet and its association with gastric cancer: health benefits from a Planeterranean perspective.Journal of translational medicine · 2024Review
- Anti-Tumor Effects and Toxicity Reduction Mechanisms ofMolecules (Basel, Switzerland) · 2024Review
- Harnessing Oleanolic Acid and Its Derivatives as Modulators of Metabolic Nuclear Receptors.Biomolecules · 2023Review
- Evaluating the Antioxidant Properties of the Ancient-Crop Tef (Antioxidants (Basel, Switzerland) · 2023Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Oleanolic acid (OA, 3β-hydroxyolean-12-en-28-oic acid) is a ubiquitous pentacyclic multifunctional triterpenoid, widely found in several dietary and medicinal plants. Natural and synthetic OA derivatives can modulate multiple signaling pathways including nuclear factor-κB, AKT, signal transducer and activator of transcription 3, mammalian target of rapamycin, caspases, intercellular adhesion molecule 1, vascular endothelial growth factor, and poly (ADP-ribose) polymerase in a variety of tumor cells. Importantly, synthetic derivative of OA, 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid (CDDO), and its C-28 methyl ester (CDDO-Me) and C28 imidazole (CDDO-Im) have demonstrated potent antiangiogenic and antitumor activities in rodent cancer models. These agents are presently under evaluation in phase I studies in cancer patients. This review summarizes the diverse molecular targets of OA and its derivatives and also provides clear evidence on their promising potential in preclinical and clinical situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.